[go: up one dir, main page]

DK3445849T3 - Fremgangsmåder og sammensætninger til at forbedre de anti-inflammatoriske virkninger af Interleukin-10 - Google Patents

Fremgangsmåder og sammensætninger til at forbedre de anti-inflammatoriske virkninger af Interleukin-10 Download PDF

Info

Publication number
DK3445849T3
DK3445849T3 DK17786683.7T DK17786683T DK3445849T3 DK 3445849 T3 DK3445849 T3 DK 3445849T3 DK 17786683 T DK17786683 T DK 17786683T DK 3445849 T3 DK3445849 T3 DK 3445849T3
Authority
DK
Denmark
Prior art keywords
interleukin
enhancing
compositions
methods
inflammatory effects
Prior art date
Application number
DK17786683.7T
Other languages
English (en)
Inventor
John Forsayeth
Raymond Chavez
Linda Watkins
Peter Grace
Original Assignee
Xalud Therapeutics Inc
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xalud Therapeutics Inc, Univ Colorado Regents filed Critical Xalud Therapeutics Inc
Application granted granted Critical
Publication of DK3445849T3 publication Critical patent/DK3445849T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
DK17786683.7T 2016-04-22 2017-04-21 Fremgangsmåder og sammensætninger til at forbedre de anti-inflammatoriske virkninger af Interleukin-10 DK3445849T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662326082P 2016-04-22 2016-04-22
PCT/US2017/028755 WO2017184933A1 (en) 2016-04-22 2017-04-21 Methods and compositions to enhance the anti-inflammatory effects of interleukin 10

Publications (1)

Publication Number Publication Date
DK3445849T3 true DK3445849T3 (da) 2024-08-05

Family

ID=60116475

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17786683.7T DK3445849T3 (da) 2016-04-22 2017-04-21 Fremgangsmåder og sammensætninger til at forbedre de anti-inflammatoriske virkninger af Interleukin-10

Country Status (11)

Country Link
US (2) US20190112354A1 (da)
EP (1) EP3445849B1 (da)
JP (2) JP7163189B2 (da)
KR (1) KR102430455B1 (da)
CN (1) CN109477085B (da)
AU (1) AU2017252327B2 (da)
CA (1) CA3019846A1 (da)
DK (1) DK3445849T3 (da)
IL (1) IL262195B2 (da)
RU (1) RU2731160C2 (da)
WO (1) WO2017184933A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3369435B1 (en) 2013-07-18 2019-09-04 Xalud Therapeutics, Inc. Composition for the treatment of inflammatory joint disease
WO2019226519A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
CA3087238A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
US20220378025A1 (en) * 2019-11-11 2022-12-01 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric genes
EP4329734A4 (en) 2021-04-26 2025-04-02 Celanese EVA Performance Polymers LLC Implantable device for the delayed release of a macromolecular drug compound
KR102466921B1 (ko) * 2021-06-29 2022-11-14 주식회사 오에이티씨 인터루킨-4를 암호화하는 유전자를 포함하는 신경병증성 통증의 예방 또는 치료용 약학적 조성물
WO2023114958A1 (en) * 2021-12-16 2023-06-22 Xalud Therapeutics, Inc. Dosing regimen for il-10 encoding expression construct

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716804A (en) * 1995-04-19 1998-02-10 Schering Corporation Mammalian interleukin-10 (IL-10) super-activating receptors; and variants
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
WO2006130580A2 (en) * 2005-05-31 2006-12-07 Avigen, Inc. Mutant il-10
CN107519499A (zh) * 2010-03-23 2017-12-29 英特瑞克斯顿股份有限公司 条件表达治疗蛋白的载体，包含所述载体的宿主细胞，及其应用
US9315825B2 (en) * 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
WO2013103966A1 (en) 2012-01-06 2013-07-11 The Regents Of The University Of Colorado, A Body Corporate Methods for the treatment of multiple sclerosis and other demyelinating disorders
EP3369435B1 (en) * 2013-07-18 2019-09-04 Xalud Therapeutics, Inc. Composition for the treatment of inflammatory joint disease

Also Published As

Publication number Publication date
RU2018140988A (ru) 2020-05-22
US20190112354A1 (en) 2019-04-18
US20240352089A1 (en) 2024-10-24
JP2022169585A (ja) 2022-11-09
CA3019846A1 (en) 2017-10-26
KR102430455B1 (ko) 2022-08-05
IL262195B2 (en) 2023-09-01
RU2018140988A3 (da) 2020-05-25
EP3445849B1 (en) 2024-06-05
CN109477085A (zh) 2019-03-15
RU2731160C2 (ru) 2020-08-31
JP7163189B2 (ja) 2022-10-31
KR20190021211A (ko) 2019-03-05
IL262195B1 (en) 2023-05-01
EP3445849A4 (en) 2019-09-25
IL262195A (en) 2018-11-29
JP2019518003A (ja) 2019-06-27
EP3445849A1 (en) 2019-02-27
AU2017252327B2 (en) 2023-05-25
WO2017184933A1 (en) 2017-10-26
AU2017252327A1 (en) 2018-11-15
CN109477085B (zh) 2023-08-01

Similar Documents

Publication Publication Date Title
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3303317T3 (da) Fremgangsmåder og sammensætninger til inhibering af interaktionen af menin med MLL-proteiner
DK3612215T3 (da) Sammensætninger til behandling af lungeinflammation
DK3600270T3 (da) Forbindelser og sammensætninger til behandling af hæmatologiske lidelser
DK3119797T3 (da) Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3484469T3 (da) Sammensætninger og fremgangsmåder til potentiering af antimikrober
DK3277270T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3102555T3 (da) Sammensætninger af forbindelser og anvendelser deraf
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK3445849T3 (da) Fremgangsmåder og sammensætninger til at forbedre de anti-inflammatoriske virkninger af Interleukin-10
DK3350201T3 (da) Manipulerede fytaser og fremgangsmåder til anvendelse af samme
DK3081263T3 (da) Sammensætninger og redskaber til behandling af glaukom
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3331879T3 (da) Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
DK3394272T5 (da) Sammensætninger og fremgangsmåder til effektiv målretning af transgener
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
DK3606929T3 (da) Beta-nicotinat-ester-nukleotider og fremgangsmåder til fremstilling af samme
DK3143026T3 (da) Forbindelser og sammensætninger til induktion af chondrogenese
DK3807316T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer
DK3522873T3 (da) Sammensætninger og fremgangsmåder til behandlingen af xerostomi
DK4101454T3 (da) Sammensætninger til behandling af hypertension
DK3638293T5 (da) Sammensætninger til behandling af cancer